Browsing Tag
Afrezza
2 posts
Could pediatric diabetes demand unlock new commercial momentum for MannKind Corporation’s Afrezza?
Find out how Afrezza’s pediatric FDA approval could strengthen MannKind’s growth story and reshape investor sentiment today.
Biotech shake-up: can Dr. Ajay Ahuja’s appointment as CMO mark a turning point for MannKind?
Find out why MannKind (Nasdaq: MNKD) appointed Dr. Ajay Ahuja as chief medical officer and what this means for its pipeline and stock outlook.